| Assessment Status | Rapid review complete |
| HTA ID | 22010 |
| Drug | Somatrogon |
| Brand | Ngenla® |
| Indication | For the treatment of children and adolescents from three years of age with growth disturbance due to insufficient secretion of growth hormone |
| Assessment Process | |
| Rapid review commissioned | 15/02/2022 |
| Rapid review completed | 25/03/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that somatrogon be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement – November 2022.
